[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 51
1. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikule N, Kasemsarn C, Patumanond J: Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival. ISRN Surg; 2013;2013:175304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival.
  • Background. Although early stage non-small cell lung cancer (NSCLC) has an excellent outcome and correlated with good long-term survival, up to 15 percent of patients still relapse postoperatively and die.
  • Multivariable analysis revealed stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases as significant prognostic factors affecting long-term survival.
  • The hazard ratio (HR) of tumor necrosis, tumor recurrence, brain metastasis, adrenal metastases, and skin metastases was 2.0, 2.3, 7.6, 4.1, and 8.3, respectively, and all P values were less than 0.001.
  • Conclusions. Our study shows stage of disease, tumor necrosis, tumor recurrence, brain metastasis, adrenal metastasis, and skin metastasis as the independent prognostic factors of long-term survival in pathological N0 NSCLC.
  • Early stage NSCLC patients without nodal involvement or presented with tumor necrosis should benefit from adjuvant chemotherapy, and sites of metastasis could predict the long-term survival as described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24073341.001).
  • [ISSN] 2090-5785
  • [Journal-full-title] ISRN surgery
  • [ISO-abbreviation] ISRN Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC3773441
  •  go-up   go-down


2. Ronchi CL, Sbiera S, Leich E, Tissier F, Steinhauer S, Deutschbein T, Fassnacht M, Allolio B: Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab; 2012 Dec;97(12):E2251-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our objective was to analyze SGK1 expression in adrenocortical tumors and to further characterize its role in ACTH-independent cortisol secretion, tumor progression, and prognosis.
  • DESIGN AND SETTING: Gene expression levels of SGK1, SGK3, and CTNNB1 (coding for β-catenin) and protein expression levels of SGK1, nuclear β-catenin, and phosphorylated AKT were determined in adrenocortical tumors and normal adrenal glands.
  • PATIENTS: A total of 227 adrenocortical tumors (40 adenomas and 187 carcinomas) and 25 normal adrenal tissues were included.
  • Among them, 62 frozen tumor samples were used for mRNA analysis and 203 tumors were investigated on tissue microarrays or full standard slides by immunohistochemistry.
  • Low SGK1 protein levels, but not nuclear β-catenin and phosphorylated AKT, were associated with poor overall survival in patients with adrenocortical carcinoma (P < 0.005; hazard ratio = 2.0; 95% confidence interval = 1.24-3.24), independent of tumor stage and GC secretion.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / genetics. Carcinoma / diagnosis. Carcinoma / genetics. Glucocorticoids / secretion. Immediate-Early Proteins / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Adenoma / metabolism. Adenoma / mortality. Adrenocorticotropic Hormone / pharmacology. Adult. Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Hydrocortisone / secretion. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):117-23 [11231987.001]
  • [Cites] MMW Fortschr Med. 2010 Feb 18;152(7):39-41 [20364508.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Mol Cell Biol. 1993 Apr;13(4):2031-40 [8455596.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):477-83 [15679045.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4366-70 [15855265.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):738-45 [15981206.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] Physiol Rev. 2006 Oct;86(4):1151-78 [17015487.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2711-23 [16857744.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):707-21 [17571248.001]
  • [Cites] Mol Endocrinol. 2007 Oct;21(10):2403-15 [17595317.001]
  • [Cites] Curr Mol Med. 2008 Feb;8(1):51-9 [18289013.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] Oncogene. 2008 Sep 1;27(38):5110-4 [18758479.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89 [19500769.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2009 Sep;18(5):439-48 [19584721.001]
  • [Cites] Endocr Relat Cancer. 2009 Sep;16(3):907-18 [19240185.001]
  • [Cites] J Mol Med (Berl). 2009 Dec;87(12):1221-39 [19756449.001]
  • [Cites] Endocrinology. 2010 Mar;151(3):1177-86 [20080870.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Oct;42(10):1571-5 [20541034.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Oct;95(10):E161-71 [20660055.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32 [20668036.001]
  • [Cites] PLoS One. 2010;5(11):e13840 [21079778.001]
  • [Cites] J Cell Sci. 2011 Jan 1;124(Pt 1):100-12 [21147854.001]
  • [Cites] Clin Cancer Res. 2011 Jan 15;17(2):328-36 [21088256.001]
  • [Cites] Nat Rev Endocrinol. 2011 Jun;7(6):323-35 [21386792.001]
  • [Cites] Oncogene. 2011 Jul 14;30(28):3198-206 [21478911.001]
  • [Cites] J Endocrinol. 2011 Oct;211(1):17-25 [21602312.001]
  • [Cites] Prostate. 2012 Feb 1;72(2):157-64 [21563193.001]
  • [Cites] Endocr Pract. 2011 Nov-Dec;17(6):941-8 [21742609.001]
  • [Cites] J Exp Clin Cancer Res. 2012;31:4 [22240294.001]
  • [Cites] Adv Exp Med Biol. 2012;727:305-19 [22399357.001]
  • [Cites] J Clin Endocrinol Metab. 2012 Apr;97(4):1194-201 [22278423.001]
  • [Cites] Neoplasia. 2012 Mar;14(3):206-18 [22496620.001]
  • [Cites] Am J Physiol Renal Physiol. 2012 Apr 15;302(8):F977-85 [22301619.001]
  • [Cites] PLoS One. 2012;7(5):e37111 [22590650.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • (PMID = 23055545.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucocorticoids; 0 / Immediate-Early Proteins; 9002-60-2 / Adrenocorticotropic Hormone; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC3579951
  •  go-up   go-down


3. Legro RS, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Brindle E, Vesper HW, Botelho JC, Lee PA, Dodson WC: Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study. J Clin Endocrinol Metab; 2017 Jan 01;102(1):122-131
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main Outcome Measures: We measured integrated urinary levels of adrenal (dehydroepiandrosterone sulfate) and ovarian [testosterone (TT)] steroids.
  • Conclusions: Matched for pubertal stage, PCOS daughters have similar levels of urinary androgens and gonadotropins as well as glucose-challenged salivary insulin levels.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • MedlinePlus Health Information. consumer health - Puberty.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3396-402 [18559912.001]
  • [Cites] Pediatrics. 2001 Aug;108(2):347-53 [11483799.001]
  • [Cites] Nat Commun. 2015 Aug 18;6:7502 [26284813.001]
  • [Cites] Hum Reprod. 2012 Feb;27(2):531-40 [22114112.001]
  • [Cites] Diabetes. 1993 Oct;42(10):1462-8 [8375585.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1662-9 [18270257.001]
  • [Cites] J Clin Endocrinol Metab. 2014 Dec;99(12):4375 [25354278.001]
  • [Cites] Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30 [7258262.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1994;68(3):200-4 [8039515.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14956-60 [9843997.001]
  • [Cites] J Clin Endocrinol Metab. 2010 May;95(5):2180-6 [20228162.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5702-5 [12466374.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Sep;94(9):3282-8 [19567527.001]
  • [Cites] J Clin Endocrinol Metab. 2015 Nov;100(11):4048-58 [26401593.001]
  • [Cites] J Pediatr. 2000 Dec;137(6):826-32 [11113840.001]
  • [Cites] Clin Biochem. 2006 Nov;39(11):1071-9 [17010960.001]
  • [Cites] Clin Chem. 2004 May;50(5):924-32 [15105350.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92 (7):2500-5 [17405838.001]
  • [Cites] Obstet Gynecol. 2014 Jul;124(1):16-22 [24901276.001]
  • [Cites] Lancet. 1973 May 5;1(7810):1007 [4121573.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2122-6 [15802312.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):235-9 [12151143.001]
  • [Cites] Fertil Steril. 2006 Oct;86(4):914-33 [16963034.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2068-73 [16492692.001]
  • [Cites] Nat Commun. 2015 Sep 29;6:8464 [26416764.001]
  • [Cites] Eur J Cancer. 1980 Apr;16(4):519-25 [6447072.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Nov;67(5):986-91 [2972739.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92 [24151290.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Dec;92(12):4637-42 [17848407.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):1923-30 [19223518.001]
  • [Cites] Pediatr Diabetes. 2002 Mar;3(1):4-9 [15016168.001]
  • [Cites] Diabetes. 2002 Oct;51(10):3014-9 [12351441.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2100-4 [16219714.001]
  • [Cites] Nat Genet. 2012 Sep;44(9):1020-5 [22885925.001]
  • (PMID = 27778640.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD042828; United States / NICHD NIH HHS / HD / U54 HD034449; United States / NCATS NIH HHS / TR / UL1 TR000127; United States / NCATS NIH HHS / TR / UL1 TR002014
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Insulin; 3XMK78S47O / Testosterone
  •  go-up   go-down


Advertisement
4. Qin J, Li G, Zhou J: Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision. Int J Chron Obstruct Pulmon Dis; 2016;11:1515-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision.
  • OBJECTIVE: To investigate the clinical features, diagnosis, and treatment status of elderly patients with chronic obstructive pulmonary disease (COPD) complicated with lung cancer.
  • PATIENTS AND METHODS: This was a retrospective study of 206 patients aged >60 years with COPD and newly diagnosed lung cancer at the Tianjin Chest Hospital Respiratory Centre between September 2008 and September 2013.
  • Multivariate analysis showed that age (P<0.001), COPD grades (P=0.01), clinical staging (P<0.001), and pulmonary diffusion function (P=0.007) were independent factors associated with patients with COPD being given treatments for lung cancer.
  • CONCLUSION: Younger patients with lower COPD grades, earlier lung cancer stage, and better pulmonary diffusion function are more likely to receive treatments.
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Age Factors. Aged. Bronchodilator Agents / administration & dosage. China / epidemiology. Female. Health Status. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Grading. Neoplasm Staging. Odds Ratio. Patient Selection. Pulmonary Diffusing Capacity. Retrospective Studies. Risk Factors. Smoking / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2011 May 1;183(9):1138-46 [21177883.001]
  • [Cites] Chest. 2013 May;143(5 Suppl):e78S-92S [23649455.001]
  • [Cites] Chest. 2002 Apr;121(4):1155-8 [11948046.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55 [19729663.001]
  • [Cites] Chest. 2007 Dec;132(6):1932-8 [18079226.001]
  • [Cites] COPD. 2010 Apr;7(2):117-25 [20397812.001]
  • [Cites] N Engl J Med. 2009 Jun 4;360(23):2445-54 [19494220.001]
  • [Cites] Thorax. 2004 Aug;59(8):679-81 [15282388.001]
  • [Cites] Am J Respir Crit Care Med. 2011 Oct 15;184(8):913-9 [21799072.001]
  • [Cites] Semin Roentgenol. 2005 Apr;40(2):90-7 [15898407.001]
  • [Cites] Chest. 2003 May;123(5):1684-92 [12740290.001]
  • [Cites] Lancet. 2007 Sep 1;370(9589):741-50 [17765523.001]
  • [Cites] Curr Opin Pulm Med. 2012 Mar;18(2):131-7 [22262137.001]
  • [Cites] Ann Intern Med. 2011 Aug 2;155(3):179-91 [21810710.001]
  • [Cites] BMC Pulm Med. 2014 Feb 05;14:14 [24498965.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Apr 1;175(7):712-9 [17185647.001]
  • [Cites] Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65 [22878278.001]
  • [Cites] Lung Cancer. 2011 Feb;71(2):182-5 [20554345.001]
  • [Cites] Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91 [25522175.001]
  • [Cites] Respirology. 2003 Mar;8(1):17-21 [12856737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56 [21640513.001]
  • [Cites] N Engl J Med. 2011 Aug 4;365(5):395-409 [21714641.001]
  • [Cites] CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 [24399786.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):775-89 [17314337.001]
  • [Cites] Prim Care Respir J. 2010 Mar;19(1):57-61 [19756330.001]
  • [Cites] Am J Epidemiol. 1999 Jan 1;149(1):13-20 [9883789.001]
  • [Cites] Eur Respir J. 2008 Apr;31(4):869-73 [18216052.001]
  • (PMID = 27445471.001).
  • [ISSN] 1178-2005
  • [Journal-full-title] International journal of chronic obstructive pulmonary disease
  • [ISO-abbreviation] Int J Chron Obstruct Pulmon Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Bronchodilator Agents; Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC4938239
  • [Keywords] NOTNLM ; chronic obstructive pulmonary disease / diagnosis / lung cancer / treatment
  •  go-up   go-down


5. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE: Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol; 2016 Apr;11(4):556-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Activating mutations in the epidermal growth factor receptor gene (EGFR) predict for prolonged progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) versus chemotherapy.
  • METHODS: Patients with EGFR-mutant metastatic lung adenocarcinoma who had been treated with erlotinib or gefitinib at Dana-Farber Cancer Institute between 2002 and 2009 were included.
  • Age; sex; stage at diagnosis; liver, bone, or adrenal metastasis; specific TKI; and line of TKI therapy were not associated with OS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Massachusetts / epidemiology. Middle Aged. Mutation. Neoplasm Metastasis. Randomized Controlled Trials as Topic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Transl Lung Cancer Res. 2016 Dec;5(6):727-730 [28149768.001]
  • (PMID = 26724471.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / 5R01-CA114465; United States / NCI NIH HHS / CA / P50CA090578
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Adenocarcinoma of lung
  • [Other-IDs] NLM/ NIHMS769302; NLM/ PMC4979601
  • [Keywords] NOTNLM ; EGFR / Non–small cell lung cancer / TKI / long-term survival
  •  go-up   go-down


6. Williams AR, Hammer GD, Else T: Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol; 2014 Jun;170(6):829-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.
  • The utility, sensitivity, and effect on patient outcome of transcutaneous adrenal biopsy (TAB) for single, large, adrenal masses are unclear.
  • We evaluated the sensitivity of TAB for tumors with the final pathological diagnosis of ACC.
  • We compared the characteristics and survival of patients with stage I-III disease who underwent TAB with those who did not undergo TAB.
  • For stage I-III patients, baseline characteristics, stage at diagnosis, and adjuvant treatment with mitotane or radiation were not significantly different between the TAB (n=36) and the non-TAB (n=254) groups.
  • CONCLUSIONS: TAB of single, large, adrenal masses is usually unnecessary, exposes patients to risk, but does not affect recurrence-free or overall survival.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2014 European Society of Endocrinology.
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1713-22 [19190108.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2816-23 [19402169.001]
  • [Cites] Eur J Endocrinol. 2009 Oct;161(4):513-27 [19439510.001]
  • [Cites] Surgery. 2009 Dec;146(6):1158-66 [19958944.001]
  • [Cites] World J Surg. 2010 Jun;34(6):1380-5 [20372905.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Oct;95(10):E161-71 [20660055.001]
  • [Cites] Dtsch Arztebl Int. 2010 Dec;107(50):885-91 [21246024.001]
  • [Cites] Eur J Endocrinol. 2011 Jun;164(6):851-70 [21471169.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1477-84 [20675074.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84 [21917861.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Dec;98(12):4551-64 [24081734.001]
  • [Cites] J Clin Endocrinol Metab. 2014 Feb;99(2):455-61 [24302750.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Hum Pathol. 2003 Feb;34(2):180-6 [12612887.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] AJR Am J Roentgenol. 1980 Feb;134(2):323-30 [6766240.001]
  • [Cites] Urology. 1981 Oct;18(4):412-6 [7292830.001]
  • [Cites] AJR Am J Roentgenol. 1981 Oct;137(4):757-61 [6974972.001]
  • [Cites] AJR Am J Roentgenol. 1982 Jun;138(6):1143-8 [6979217.001]
  • [Cites] Radiology. 1983 Aug;148(2):566 [6867360.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1058-60 [6692299.001]
  • [Cites] Cancer. 1984 May 15;53(10):2098-103 [6704899.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):269-82 [6587703.001]
  • [Cites] AJR Am J Roentgenol. 1984 Nov;143(5):1081-4 [6385672.001]
  • [Cites] AJR Am J Roentgenol. 1985 Jan;144(1):67-9 [3871150.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jan-Feb;9(1):217-8 [3968274.001]
  • [Cites] Radiology. 1989 May;171(2):493-6 [2704815.001]
  • [Cites] Dtsch Med Wochenschr. 1990 Feb 9;115(6):212-5 [2406116.001]
  • [Cites] AJR Am J Roentgenol. 1991 Oct;157(4):777-80 [1892034.001]
  • [Cites] Acta Radiol. 1991 Sep;32(5):371-4 [1910990.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1991;137:31-4 [1947837.001]
  • [Cites] Arch Pathol Lab Med. 1992 Aug;116(8):841-6 [1497466.001]
  • [Cites] Radiology. 1993 Jun;187(3):715-8 [8497619.001]
  • [Cites] Am J Med. 1993 Aug;95(2):244-5 [8356992.001]
  • [Cites] Radiology. 1994 Nov;193(2):341-4 [7972740.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):434-9 [7790554.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):460-84 [8521790.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4 [16895957.001]
  • [Cites] AMIA Annu Symp Proc. 2006;:941 [17238560.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Surgery. 2007 Oct;142(4):497-502; discussion 502-4 [17950341.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89 [19500769.001]
  • (PMID = 24836548.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK020572; United States / NIDDK NIH HHS / DK / T32 DK007245; United States / NIDDK NIH HHS / DK / T32-DK007245
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ NIHMS576377; NLM/ PMC4096775
  •  go-up   go-down


7. Plönes T, Osei-Agyemang T, Krohn A, Passlick B: Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer. Indian J Surg; 2015 Dec;77(Suppl 2):216-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer.
  • The prognosis of metastatic non-small cell lung cancer (NSCLC) is poor, and platinum-based chemotherapy improves the median survival for only a few months.
  • Fifty-six patients underwent surgical resection for oligometastatic lung cancer.
  • Analyzing the influence of metastatic site, we found a median overall survival of 23.4 months for patients with soft tissue metastasis, 16.7 months for patients with brain metastasis, 9.5 months for patients with adrenal gland involvement, and only 4.3 months for patients with bone metastasis (p < 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26729996.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4692853 [Available on 12/01/16]
  • [Keywords] NOTNLM ; NSCLC / Single metastasis / Skip metastasis / Stage
  •  go-up   go-down


8. Huang SH, Kong QL, Chen XX, He JY, Qin J, Chen ZG: Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer. Ther Clin Risk Manag; 2017;13:355-360
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer.
  • BACKGROUND AND PURPOSE: Several case reports and studies have suggested that there is an increased survival rate for patients who undergo resection of solitary adrenal metastasis from non-small cell lung cancer (NSCLC).
  • This study aimed to investigate whether NSCLC patients with solitary adrenal metastasis could gain a higher survival rate after adrenalectomy (ADX) when compared with those patients undergoing nonsurgical treatment, and to investigate the potential prognostic factors.
  • PATIENTS AND METHODS: A total of 1,302 NSCLC inpatients' data from 2001 to 2015 were retrospectively reviewed to identify those with solitary adrenal metastasis.
  • RESULTS: A total of 22 NSCLC patients with solitary adrenal metastasis were identified, with an overall median survival of 11 months (95% confidence interval: 9.4-12.6 months) and a 1-year survival rate of 51.4% (95% confidence interval: 29.6%-73.2%).
  • Age (<65 vs ≥65 years), sex, pathologic type, mediastinal lymph node stage (N2 vs N0/N1), primary tumor size (<5 vs ≥5 cm), primary location (central vs peripheral), metastatic tumor size (<5 vs ≥5 cm), metastasis laterality, synchronous metastasis, and metastatic field radiotherapy were not identified as potential prognostic factors in relation to survival rate.
  • CONCLUSION: Primary and metastatic radical resection may not prolong the survival of NSCLC patients with solitary adrenal metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1142-7 [18309950.001]
  • [Cites] Am J Case Rep. 2014 Oct 15;15:444-6 [25317919.001]
  • [Cites] World J Surg. 2006 May;30(5):888-92 [16547618.001]
  • [Cites] Cancer Treat Res. 2016;170:47-75 [27535389.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jul;130(1):136-40 [15999053.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3392-400 [17665267.001]
  • [Cites] Eur J Surg Oncol. 2010 Jul;36(7):699-704 [20452170.001]
  • [Cites] Am J Clin Oncol. 2011 Jun;34(3):249-53 [20498589.001]
  • [Cites] World J Surg. 2012 Jun;36(6):1400-5 [22411083.001]
  • [Cites] Eur J Cardiothorac Surg. 2012 Mar;41(3):617-22 [22223700.001]
  • [Cites] Lung Cancer. 2005 Aug;49(2):203-7 [16022914.001]
  • [Cites] Lung Cancer. 2013 Oct;82(1):95-102 [23973202.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):981-5 [11269485.001]
  • [Cites] Ann Thorac Surg. 2011 Nov;92(5):1788-92; discussion 1793 [21944257.001]
  • (PMID = 28356749.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; adrenalectomy / non-small cell lung cancer / prognostic factors / solitary metastasis / survival
  •  go-up   go-down


9. Custódio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC: Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol; 2013 Jul 10;31(20):2619-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors were smaller in surveillance participants (P < .001) and more advanced in nonparticipants (four with stage III disease; two deaths).
  • Cancer histories and pedigrees were obtained for 353 families that included 1,704 identified carriers.
  • ACTs were the most frequent cancer among carrier children (n = 48).

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Mol Cell Endocrinol. 2012 Mar 31;351(1):44-51 [22056871.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1047-53 [11932471.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Mar;62(1):127-30 [15122446.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1176-81 [7981072.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):175-8 [9024511.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2004 Oct;48(5):647-50 [15761534.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1118-24 [16077069.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1274-9 [16244654.001]
  • [Cites] J Med Genet. 2006 Jan;43(1):91-6 [16033918.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):56-60 [16200634.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5056-62 [16707427.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83 [17380161.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):21-5 [18248785.001]
  • [Cites] Pediatrics. 2009 Jan;123(1):407-12 [19117908.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1250-6 [19204208.001]
  • [Cites] Lancet Oncol. 2009 Sep;10(9):920-5 [19717094.001]
  • [Cites] J Med Genet. 2010 Jun;47(6):421-8 [20522432.001]
  • [Cites] PLoS One. 2011;6(3):e18015 [21445348.001]
  • [Cites] Cancer. 2011 May 15;117(10):2228-35 [21192060.001]
  • [Cites] Lancet Oncol. 2011 Jun;12(6):559-67 [21601526.001]
  • [Cites] Mol Cell Endocrinol. 2012 Mar 31;351(1):101-10 [21930187.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • (PMID = 23733769.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA021765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC3808236
  •  go-up   go-down


10. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM: Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg; 2010 Sep;395(7):955-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
  • We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.
  • METHODS: A retrospective review of patients included in the University of Michigan ACC database from 2005 to 2009 was done; and stage, tumor grade, time to recurrence, and death were recorded and analyzed using the Cox regression and Kaplan-Meier survival curves.
  • There were 28 deaths; overall, tumor grade showed a significant difference in time to tumor recurrence (p = 0.011) and time to death (p = 0.004).
  • Time to death among stage 2 patients separated into those with high- and low-grade tumors reached statistical significance (p = 0.05), and notable but not statistically significant differences were identified in all stages.
  • Based on tumor grade and survival curves, modifications to the current ENSAT staging system were made.
  • CONCLUSION: Tumor grade plays a significant role in the outcome of patients with ACC.
  • The proposed modification of the ENSAT staging system allows for incorporation of tumor grade when predicting overall survival.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Staging / trends

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2005 Dec;138(6):1078-85; discussion 1085-6 [16360394.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):713-9 [20044246.001]
  • [Cites] Oncologist. 2008 May;13(5):548-61 [18515740.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Surg Clin North Am. 2009 Oct;89(5):1255-67 [19836496.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] World J Surg. 2010 Jun;34(6):1380-5 [20372905.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):668-76 [19147773.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Surgery. 1992 Dec;112(6):972-9; discussion 979-80 [1455322.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):263-70 [19851811.001]
  • (PMID = 20694732.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement